Datametrex AI Limited (the
“
Company” or “
Datametrex”)
(
TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to
announce that President and Dean of the Toronto Institute of
Pharmaceutical Technology (
“TIPT”) and Clinical
Pharmacologist, Dr. Alexander MacGregor, Ph.D., a, has consented to
join the Company's Medical Advisory Board.
The Company is also in discussion with
Transpharm Canada Inc. (“TCI”), the parent company
of Toronto Institute of Pharmaceutical Technology to provide lab
testing services using there fully compliant Health Canada licensed
Good Manufacturing Practice (“GMP”) manufacturing
and testing facility located in Toronto, ON, Canada. Having a mass
testing partner will be a key growth driver for the Company and
will be working to solidify an agreement on this prospective joint
project.
Datametrex is extremely pleased to have an
medical patent holder and pharmacologist with the experience and
abilities of Dr. MacGregor join its Medical Advisory Board," said
Marshall Gunter, CEO of Datametrex. "Alexander will be an excellent
source of advice as the Company advances a key part of covid-19
with lab capacity and his and his teams pharmacology expertise. We
welcome Dr. MacGregor and look forward to his valued contribution
as the newest member of our team."
Dr. Alexander MacGregor stated, “I am very
pleased to join the Company’s medical advisory board. With this
unprecedented pandemic terribly affecting people worldwide and has
temporarily changed the way the world operates, I am pleased to be
assisting Datametrex with my teams expertise in lab testing on the
front lines and assisting developing a plan to meet the enormous
demand coming in COVID-19 testing and working on lowering the curve
during this outbreak.”
About Dr. Alexander
MacGregor
A leader in the fields of pharmaceutical
technology, research, and training, Dr. MacGregor has served as the
President and Dean of Faculty of the Toronto Institute of
Pharmaceutical Technology (TIPT®) since 1992.
The holder of several scientific patents, Dr.
MacGregor currently oversees clinical testing trials of several
drugs in the areas of cholesterol lowering, diabetes,
anti-infective, post-operative pain, epilepsy, and congestive heart
failure.
Dr. MacGregor obtained his Ph.D. in clinical
pharmacology from the University of London Postgraduate Medical
School after earning B.Sc. (Honors) in Medical Biochemistry from
the Cardif University in Wales. In 1997, Dr. MacGregor completed a
Master-Class Certification Program in Pharmaceutical Technology
from the European Continuing Education College at the University of
Liverpool.
In 1990, Dr. MacGregor moved to Canada to assume
the role of managing director of Transpharm International UK Ltd.,
a scientific enterprise specializing in clinical testing and
pharmaceutical drug licensing. Throughout the decade, Dr. MacGregor
functioned as a consultant to major pharmaceutical industries in
Europe, Asia, and North America.
Dr. MacGregor currently divides his time between
TIPT, one of North America's leading postgraduate pharmaceutical
and research organizations, and ORx Pharmaceutical Corporation,
where he serves as chairman and Chief Scientific Officer. In the
latter capacity, Dr. MacGregor designs and develops clinical
delivery methods of therapeutic compounds.
At TIPT, Dr. MacGregor runs a highly regarded
training program in pharmaceutical sciences and technology. More
than 7,500 successful TIPT graduates operate in all areas of the
pharmaceutical industry including quality control analysis,
regulatory affairs administration, clinical quality control, and
clinical data review.
An active humanitarian within the
African-Canadian community, Dr. MacGregor supports such
organizations as the Canadian Association of Black Lawyers (CABL)
and the Association of Black Law Enforcers (ABLE). Dr. MacGregor
also donates generously to charities such as the United Way and the
Nelson Mandela Children's fund.
About Datametrex
Datametrex AI Limited is a technology focused
company with exposure to Artificial Intelligence and Machine
Learning through its wholly owned subsidiary, Nexalogy
(www.nexalogy.com).
Additional information on Datametrex is
available at www.datametrex.com
For further information, please
contact:
Marshall Gunter – CEOPhone: (514) 295-2300Email:
mgunter@datametrex.com
Neither the TSX Venture Exchange nor it's
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws. All
statements contained herein that are not clearly historical in
nature may constitute forward-looking information. In some cases,
forward-looking information can be identified by words or phrases
such as “may”, “will”, “expect”, “likely”, “should”, “would”,
“plan”, “anticipate”, “intend”, “potential”, “proposed”,
“estimate”, “believe” or the negative of these terms, or other
similar words, expressions and grammatical variations thereof, or
statements that certain events or conditions “may” or “will”
happen, or by discussions of strategy.
Readers are cautioned to consider these and
other factors, uncertainties and potential events carefully and not
to put undue reliance on forward-looking information. The
forward-looking information contained herein is made as of the date
of this press release and is based on the beliefs, estimates,
expectations and opinions of management on the date such
forward-looking information is made. The Company undertakes no
obligation to update or revise any forward-looking information,
whether as a result of new information, estimates or opinions,
future events or results or otherwise or to explain any material
difference between subsequent actual events and such
forward-looking information, except as required by applicable
law.
DataMetrex AI (TSXV:DM)
Historical Stock Chart
From Mar 2024 to Apr 2024
DataMetrex AI (TSXV:DM)
Historical Stock Chart
From Apr 2023 to Apr 2024